Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Syros Reports Third Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
November 1, 2018 7:00 AM EDTOpened Expansion Cohorts in Phase 1 Trial Evaluating SY-1365 in Multiple Ovarian and Breast Cancer Populations as Single Agent and in Combination
Selected Oral CDK7 Inhibitor SY-5609 as Development Candidate to Enter IND-Enabling Studies
Dose Escalation Data from Phase 1 Trial of SY-1365 to be Presented at EORTC-NCI-AACR and Initial Clinical Data from Combination Arms of Phase 2 Trial of SY-1425 to be Presented at ASH
Management to Host Conference Call at 7:30 AM ET Today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:... More
